Michel Vounatsos
Net Worth

Last updated:

What is Michel Vounatsos net worth?

The estimated net worth of Mr. Michel Vounatsos is at least $40,909,888 as of 18 Feb 2022. He owns shares worth $4,829,888 as insider and has received compensation worth at least $36,080,000 in Biogen Inc..

What is the salary of Michel Vounatsos?

Mr. Michel Vounatsos salary is $4,510,000 per year as Chief Executive Officer & Director in Biogen Inc..

How old is Michel Vounatsos?

Mr. Michel Vounatsos is 63 years old, born in 1962.

What stocks does Michel Vounatsos currently own?

As insider, Mr. Michel Vounatsos owns shares in one company:

Company Title Shares Price per share Total value
Biogen Inc. (BIIB) Chief Executive Officer & Director 34,810 $138.75 $4,829,888

What does Biogen Inc. do?

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

BIIB logo
BIIB
Biogen Inc.
$138.75

Michel Vounatsos insider trading

Biogen Inc.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 6,191 N/A N/A
Option
Restricted Stock Unit 6,191 N/A N/A
Option
Restricted Stock Unit 16,289 N/A N/A
Option
Restricted Stock Unit 16,289 N/A N/A
Option
Common Stock 16,289 N/A N/A
Option
Common Stock 16,289 N/A N/A
Purchase
Common Stock 3,100 $241.31 $748,046
Option
Common Stock 4,847 N/A N/A
Option
Restricted Stock Unit 4,847 N/A N/A
Option
Restricted Stock Unit 11,994 N/A N/A
Option
Common Stock 11,994 N/A N/A
Option
Common Stock 1,480 N/A N/A
Option
Restricted Stock Unit 1,480 N/A N/A
Purchase
Common Stock 4,351 $231.48 $1,007,169
Option
Common Stock 5,269 N/A N/A
Option
Restricted Stock Unit 5,269 N/A N/A
Option
Common Stock 6,899 N/A N/A
Option
Restricted Stock Unit 6,899 N/A N/A
Option
Restricted Stock Unit 1,687 N/A N/A
Option
Common Stock 1,687 N/A N/A
Option
Restricted Stock Unit 5,354 N/A N/A
Option
Common Stock 5,354 N/A N/A
Purchase
Common Stock 780 $320.55 $250,029
Option
Restricted Stock Unit 1,736 N/A N/A
Option
Common Stock 1,736 N/A N/A
Purchase
Common Stock 1,402 $271.35 $380,433
Purchase
Common Stock 1,333 $285.39 $380,425

Biogen key executives

Biogen Inc. executives and other stock owners filed with the SEC: